Dual MEK/AKT inhibition with trametinib and GSK2141795 does not yield clinical benefit in metastatic NRAS-mutant and wild-type melanoma

Phase I dose-escalation of the oral MEK1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral AKT inhibitor GSK2141795 (GSK795).

(2017) R. Kurzrock et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies

(2016) Alain P. Algazi et al.   CANCER

Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma

(2016) Antoni Ribas et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Association BetweenNRASandBRAFMutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma

(2015) Nancy E. Thomas et al.   JAMA Oncology

Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma

(2014) Anthony W. Tolcher et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors

(2014) P. L. Bedard et al.   CLINICAL CANCER RESEARCH

Prominent role of cyclic adenosine monophosphate signalling pathway in the sensitivity of WTBRAF/WTNRAS melanoma cells to vemurafenib

(2014) Mohammad Krayem et al.   EUROPEAN JOURNAL OF CANCER

Effect of Selumetinib vs Chemotherapy on Progression-Free Survival in Uveal Melanoma

(2014) Richard D. Carvajal et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma

(2014) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study

(2013) Paolo A Ascierto et al.   LANCET ONCOLOGY

BRAF/NRASMutation Frequencies Among Primary Tumors and Metastases in Patients With Melanoma

(2012) Maria Colombino et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial

(2012) Jeffrey R Infante et al.   LANCET ONCOLOGY

RASMutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors

(2012) Fei Su et al.   NEW ENGLAND JOURNAL OF MEDICINE

High-Throughput Detection of Actionable Genomic Alterations in Clinical Tumor Samples by Targeted, Massively Parallel Sequencing

(2011) Nikhil Wagle et al.   Cancer Discovery

Mutations inGNA11in Uveal Melanoma

(2010) Catherine D. Van Raamsdonk et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined Targeting of BRAF and CRAF or BRAF and PI3K Effector Pathways Is Required for Efficacy in NRAS Mutant Tumors

(2009) Bijay S. Jaiswal et al.   PLoS One